IronBridge Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

IronBridge Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$4M	Buy	99,470 +5,970	+6%	+$268K	0.24%	130
2016 Q4	$4.47M	Sell	93,500 -390	-0.4%	-$15.4K	0.2%	123
2016 Q3	$3.44M	Buy	93,890 +8,915	+10%	+$279K	0.16%	139
2016 Q2	$1.98M	Sell	84,975 -18,405	-18%	-$594K	0.09%	150
2016 Q1	$4.19M	Buy	+103,380	New	+$4.2M	0.17%	134
2015 Q4	–	Sell	-113,773	Closed	-$4.6M	–	181
2015 Q3	$4.6M	Sell	113,773 -2,630	-2%	-$136K	0.18%	125
2015 Q2	$6.7M	Sell	116,403 -3,070	-3%	-$195K	0.2%	114
2015 Q1	$7.61M	Sell	119,473 -124,180	-51%	-$8.43M	0.22%	113
2014 Q4	$15M	Sell	243,653 -51,760	-18%	-$2.55M	0.42%	72
2014 Q3	$11.5M	Sell	295,413 -6,830	-2%	-$242K	0.31%	89
2014 Q2	$10.4M	Sell	302,243 -31,556	-9%	-$994K	0.25%	104
2014 Q1	$14.4M	Sell	333,799 -26,221	-7%	-$1.27M	0.31%	97
2013 Q4	$14.3M	Sell	360,020 -19,356	-5%	-$690K	0.31%	102
2013 Q3	$14.2M	Buy	+379,376	New	+$11.3M	0.3%	101

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

IronBridge Capital Management's IONS Position: Q1 2017 in Review

IronBridge Capital Management increased its Ionis Pharmaceuticals (IONS) stake by 6.4% in Q1 2017, buying an estimated $268K and bringing the position to 99,470 shares worth $4M. The position accounts for 0.24% of the portfolio, ranked #130.

IronBridge Capital Management first reported a position in IONS in Q3 2013 and has held it in 14 quarters since. The position peaked at $15M in Q4 2014. 271 funds tracked by Wall St. Rank hold IONS as of Q1 2017.

IronBridge Capital Management held 99,470 shares of Ionis Pharmaceuticals worth $4M as of Q1 2017.
IronBridge Capital Management bought 5,970 Ionis Pharmaceuticals shares in Q1 2017, an estimated $268K.
Ionis Pharmaceuticals made up 0.24% of IronBridge Capital Management's portfolio in Q1 2017, its #130 holding.
IronBridge Capital Management first reported a position in Ionis Pharmaceuticals in Q3 2013 and has held it in 14 quarters since.
IronBridge Capital Management's Ionis Pharmaceuticals position peaked at $15M in Q4 2014.
271 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2017.

Based on IronBridge Capital Management's 13F filing for Q1 2017, filed 10 May 2017.